Wednesday, September 23, 2020
wellness India Expo
Home Tags DCGI

Tag: DCGI

Jubilant launches JUBI-R, its generic version of COVID-19 drug remdesivir in...

Jubilant Generics, a subsidiary of Jubilant Life Sciences has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection)........................

DCGI nod to Serum Institute for conducting human trials of Oxford...

The Drugs Controller General of India has given the Serum Institute of India a green light to conduct phase 2 and 3 human trials of the Oxford-AstraZeneca COVID-19 vaccine candidate in India..................

Mylan secures DCGI approval for its drug-resistant TB drug, Pretomanid

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years. The approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance..................

Biophore ramps up Made-In-India Favipiravir production for Covid-19

Hyderabad-based Biophore India Pharmaceuticals has received the DCGI license to manufacture the API in India and has been cleared for export as well.................

Bharat Biotech’s COVID-19 vaccine ‘COVAXIN’ gets DCGI nod, human trials to...

Human trials of India’s first indigenous experimental vaccine against COVID-19, COVAXIN, developed by Bharat Biotech is set to begin across India in July........................

CSIR-CDRI’s COVID-19 drug candidate Umifenovir secures DCGI approval for phase III...

This drug has a good safety profile and acts by preventing the entry of virus into human cells and also by priming the immune system......................

Sun Pharma initiates Phase II clinical trial of first phytopharma drug...

Clinical trial of the drug that has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with ICGEB will be conducted across 12 centers in India in 210 patients; results expected by October 2020.............................

DCGI approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung...

Being the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need. Following the FDA’s approval in September 2019, Nintedanib in SSc-ILD has so far been approved in 15 countries including the European Union, Canada, Japan and Brazil.................

CDSCO issues alert on Medtronic’s pacemakers, company says no product recall

The CDSCO has advised patients with specific pacemakers from Medtronic to seek immediate medical assistance if they feel dizzy, light-headed, severe short breath or loss of consciousness. Meanwhile, the company has said it is in talks with the regulator............

Govt notifies new rules for clinical trials, ISCR hails the move

Aimed at reducing the market entry of drugs in India, the ones approved for use in European countries and the United States will be allowed in the country if the Indian patients are included in the earlier trials held abroad...................